Table 2.
HIV-related markers while on immune checkpoint inhibitor therapy.
| Patient | HAART regimen | CD 4 (cells/ μ l) at baseline | CD 4 (cells/ μ l) at 12 weeks | VL (copies/ml) at baseline | VL (copies/ml) at 12 weeks |
|---|---|---|---|---|---|
| 1 | FTC/TDF + DTG | 573 | NA∗ | 0 | NA∗ |
| 2 | EVG/c/FTC/TDF | 242 | NA∗ | <400 | NA∗ |
| 3 | DTG, DRV/r | 795 | 552 | <400 | 0 |
| 4 | ABC/DTG/3TC | 424 | 460 | 0 | 0 |
| 5 | FTC/TDF + DTG | 427 | 402 | 0 | <400 |
| 6 | FTC/TDF + DRV | 626 | 517 | 0 | 0 |
| 7 | ETR, DTG, DRV/r | 607 | 597 | <20 | <20 |
| 8 | EFV/FTC/TDF | 305 | NA | <20 | NA |
| 9 | FTC/TAF + DTG | NA | NA | NA | NA |
| 10 | RPV/FTC/TDF | 469 | NA∗ | <20 | NA∗ |
| 11 | FTC/TDF + DTG | 624 | NA∗ | 500 | NA∗ |
| 12 | ABC/3TC/DTG | 250 | 262 | <20 | <20 |
| 13 | FTC/TDF + DTG | 326 | 431 | 0 | 0 |
| 14 | FTC/TDF + DTG | 150 | 120 | <20 | <20 |
| 15 | TDF/RAL | 461 | 376 | <400 | <400 |
| 16 | DRV/c + DTG | 163 | 285 | 89 | <20 |
| 17 | FTC/TDF + DTG | 264 | 370 | 0 | <400 |
Abbreviations: NA: data not available. ∗: died before response could be assessed. VL: viral load.
HAART regimen: FTC/TDF: emtricitabine/tenofovir disoproxil fumarate. DTG: dolutegravir. EVG/c: elvitegravir/cobicistat. DRV/r: darunavir/ritonavir. ABC: abacavir. 3TC: lamivudine. TDF: tenofovir disoproxil fumarate. RAL: raltegravir. DRV/c: darunavir. ETR: etravirine. EFV: efavirenz. TAF: tenofovir alafenamide. RPV: rilpivirine.